CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0531 (clinicaltrials.gov NCT No: NCT01953692)
Title:A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:MK-3475
Study Status:Open
Study Description:The goal of this clinical research study is to learn more about the safety of
the study drug MK-3475. Researchers also want to learn more about if and how
the drug affects hematologic malignancies (cancers of the blood, bone marrow,
or lymph nodes, such as MDS and SMM).

In this multicenter study, 5 types of cancer will be studied. At MD Anderson,
only patients with MDS or SMM will be enrolled.

Hide details for General InformationGeneral Information

Disease Group:Leukemia; Myeloma
Phase of Study:Phase I
Treatment Agents:MK-3475
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Merck Sharp & Dohme Corp.,
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
Dept:Leukemia
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults